Duffy J M N, Bhattacharya S, Curtis C, Evers J L H, Farquharson R G, Franik S, Khalaf Y, Legro R S, Lensen S, Mol B W, Niederberger C, Ng E H Y, Repping S, Strandell A, Torrance H L, Vail A, van Wely M, Vuong N L, Wang A Y, Wang R, Wilkinson J, Youssef M A, Farquhar C M
Balliol College, University of Oxford, Oxford, UK.
Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Hum Reprod Open. 2018 Jun 15;2018(3):hoy007. doi: 10.1093/hropen/hoy007. eCollection 2018.
We aim to produce, disseminate and implement a core outcome set for future infertility research.
Randomized controlled trials (RCTs) evaluating infertility treatments have reported many different outcomes, which are often defined and measured in different ways. Such variation contributes to an inability to compare, contrast and combine results of individual RCTs. The development of a core outcome set will ensure outcomes important to key stakeholders are consistently collected and reported across future infertility research.
This is a consensus study using the modified Delphi method. All stakeholders, including healthcare professionals, allied healthcare professionals, researchers and people with lived experience of infertility will be invited to participate.
PARTICIPANTS/MATERIALS SETTING METHODS: An international steering group, including people with lived experience of infertility, healthcare professionals, allied healthcare professionals and researchers, has been formed to guide the development of this core outcome set. Potential core outcomes have been identified through a comprehensive literature review of RCTs evaluating treatments for infertility and will be entered into a modified Delphi method. Participants will be asked to score potential core outcomes on a nine-point Likert scale anchored between one (not important) and nine (critical). Repeated reflection and rescoring should promote convergence towards consensus 'core' outcomes. We will establish standardized definitions and recommend high-quality measurement instruments for individual core outcomes.
STUDY FUNDING/COMPETING INTERESTS: This project is funded by the Royal Society of New Zealand Catalyst Fund (3712235). BWM reports consultancy fees from Guerbet, Merck, and ObsEva. R.S.L. reports consultancy fees from Abbvie, Bayer, Fractyl and Ogeda and research sponsorship from Ferring. S.B. is the Editor-in-Chief of Human Reproduction Open. The remaining authors declare no competing interests.
我们旨在为未来的不孕症研究制定、传播并实施一套核心结局指标集。
评估不孕症治疗方法的随机对照试验(RCT)报告了许多不同的结局,这些结局的定义和测量方式往往各不相同。这种差异导致无法对各个随机对照试验的结果进行比较、对比和合并。制定一套核心结局指标集将确保在未来的不孕症研究中始终收集并报告对关键利益相关者重要的结局。
这是一项采用改良德尔菲法的共识研究。将邀请所有利益相关者参与,包括医疗保健专业人员、辅助医疗保健专业人员、研究人员以及有不孕症亲身经历的人。
参与者/材料设置方法:已成立一个国际指导小组,其中包括有不孕症亲身经历的人、医疗保健专业人员、辅助医疗保健专业人员和研究人员,以指导这套核心结局指标集的制定。通过对评估不孕症治疗方法的随机对照试验进行全面的文献综述,确定了潜在的核心结局,并将其纳入改良德尔菲法。将要求参与者根据1(不重要)至9(关键)的九点李克特量表对潜在的核心结局进行评分。反复思考和重新评分应促使达成共识的“核心”结局趋于一致。我们将建立标准化定义,并为各个核心结局推荐高质量的测量工具。
研究资金/利益冲突:本项目由新西兰皇家学会催化基金(3712235)资助。BWM报告收取了Guerbet、默克和ObsEva的咨询费。R.S.L.报告收取了艾伯维、拜耳、Fractyl和Ogeda的咨询费以及辉凌的研究赞助费。S.B.是《人类生殖开放》的主编。其余作者声明无利益冲突。